ArticleSmall (Weinheim an der Bergstrasse, Germany)2022
Development of Biodegradable Osteopromotive Citrate-Based Bone Putty.
Article in Small (Weinheim an der Bergstrasse, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Efficacy and safety of a novel absorbable bone wax as a hemostatic agent for periacetabular osteotomy: a prospective, randomized controlled trial.BMC musculoskeletal disorders · 2026Trial
- Engineering bioactive citrate-based hydrogels for wound repair: From structure-function design to microenvironmental regulation.Bioactive materials · 2027Review
- Targeting the osteoporotic bone microenvironment: Mechanistic insight and therapeutic biomaterials for accelerating bone regeneration.Bioactive materials · 2026Review
- Materiobiology-guided regulation of mesenchymal stromal cell fate for aging-related diseases: From basic parameter design to clinical application.Bioactive materials · 2026Review
- Pressure-sensitive composite bandages with high toughness, self-healability and strong tissues adhesion for rapid bone fixation and accelerated osteogenesis via immunomodulation and neovascularization.Materials today. Bio · 2026Article
- The genesis of citrated ultrathin hydroxyapatite nanorods.Science advances · 2026Article
- Novel Bioresorbable Bone Wax for Potentiated Hemostasis and Osteogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Anionic Citrate-Based 3D-Printed Scaffolds for Tunable and Sustained Orthobiologic Delivery to Enhance Tissue Regeneration.Advanced functional materials · 2025Article
- Metabotissugenic citrate biomaterials orchestrate bone regeneration via citrate-mediated signaling pathways.Science advances · 2025Article
- How to explain the beneficial effects of platelet-rich plasma.Periodontology 2000 · 2025Review
- Citric Acid: A Nexus Between Cellular Mechanisms and Biomaterial Innovations.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Electrospun Fenoprofen/Polycaprolactone @ Tranexamic Acid/Hydroxyapatite Nanofibers as Orthopedic Hemostasis Dressings.Nanomaterials (Basel, Switzerland) · 2024Article
- High-Resolution Additive Manufacturing of a Biodegradable Elastomer with A Low-Cost LCD 3D Printer.Advanced healthcare materials · 2024Article
- Citrate-modified bacterial cellulose as a potential scaffolding material for bone tissue regeneration.PloS one · 2024Article
- Current application and future perspectives of antimicrobial degradable bone substitutes for chronic osteomyelitis.Frontiers in bioengineering and biotechnology · 2024Review
- Recent Progress in Advanced Polyester Elastomers for Tissue Engineering and Bioelectronics.Molecules (Basel, Switzerland) · 2023Review
- Functional hydrogels for the repair and regeneration of tissue defects.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
The burden of bone fractures demands development of effective biomaterial solutions, while additional acute events such as noncompressible bleeding further motivate the search for multi-functional implants to avoid complications including osseous hemorrhage, infection, and nonunion. Bone wax has been widely used in orthopedic bleeding control due to its simplicity of use and conformation to irregular defects; however, its nondegradability results in impaired bone healing, risk of infection, and significant inflammatory responses. Herein, a class of intrinsically fluorescent, osteopromotive citrate-based polymer/hydroxyapatite (HA) composites (BPLP-Ser/HA) as a highly malleable press-fit putty is designed. BPLP-Ser/HA putty displays mechanics replicating early nonmineralized bone (initial moduli from ≈2-500 kPa), hydration induced mechanical strengthening in physiological conditions, tunable degradation rates (over 2 months), low swelling ratios (<10%), clotting and hemostatic sealing potential (resistant to blood pressure for >24 h) and significant adhesion to bone (≈350-550 kPa). Simultaneously, citrate's bioactive properties result in antimicrobial (≈100% and 55% inhibition of S. aureus and E. coli) and osteopromotive effects. Finally, BPLP-Ser/HA putty demonstrates in vivo regeneration in a critical-sized rat calvaria model equivalent to gold standard autograft. BPLP-Ser/HA putty represents a simple, off-the-shelf solution to the combined challenges of acute wound management and subsequent bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.